BLAINJECTIONINJECTABLE5 Generics Approved
Approved
Apr 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
HUMULIN 70/30 (insulin human) by Eli Lilly and Company. Approved for insulin [epc]. First approved in 1989.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMULIN 70/30 is a fixed-ratio combination insulin human (70% NPH, 30% regular) administered via injection for Type 1 and Type 2 diabetes mellitus. It regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat while inhibiting hepatic glucose production, lipolysis, and proteolysis.
LOE Approaching
Product faces LOE pressure with moderate competitive intensity (30/100); team focus shifting toward cost management and patient retention in value-based care.
Mechanism of Action
Pharmacologic Class:
Insulin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Started Jan 2011
13 enrolled
DiabetesDiabetes Mellitus, Type 1
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Started Aug 2008
28 enrolled
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Started Jul 2008
42 enrolled
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
Started Jan 2008
25 enrolled
Diabetes Mellitus
Worked on HUMULIN 70/30 at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.